Israpafant

Israpafant

SCHEMBL121587

Cc1nnc2n1-c1sc(CCc3ccc(CC(C)C)cc3)cc1C(c1ccccc1Cl)=N[C@@H]2C

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 18/20 0.69
OPRK1 P41145 1/20 0.45
PDE4D Q08499 1/20 0.45
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Israpafant SCHEMBL8792967 1.00 PTAFR (0.69) PTAFROPRK1PDE4DCYP3A4ALOX15
Israpafant SCHEMBL121588 1.00 PTAFR (0.69) PTAFROPRK1PDE4DCYP3A4ALOX15
Israpafant SCHEMBL30733966 1.00 PTAFR (0.69) PTAFROPRK1PDE4DCYP3A4ALOX15
Israpafant SCHEMBL8794591 0.99 PTAFR (0.68) PTAFROPRK1PDE4DCYP3A4ALOX15
SCHEMBL9374585 0.92 PTAFR (0.58) PTAFROPRK1PDE4DCYP3A4ALOX15
Israpafant SCHEMBL8792589 0.90 PTAFR (0.57) PTAFROPRK1PDE4DCYP3A4ALOX15
SCHEMBL8878479 0.90 PTAFR (0.67) PTAFROPRK1PDE4DCYP3A4ALOX15
SCHEMBL9374425 0.89 PTAFR (0.64) PTAFROPRK1PDE4DCYP3A4ALOX15
SCHEMBL8877687 0.89 PTAFR (0.57) PTAFROPRK1PDE4DCYP3A4ALOX15
SCHEMBL8126816 0.89 PTAFR (0.66) PTAFROPRK1PDE4DCYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 559 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962797-B2 POWDER COMPOSITIONS FOR INHALATION JAGOTEC AG (CH) 2024-05-29 EP claimed
EP-1962797-B1 POWDER COMPOSITIONS FOR INHALATION JAGOTEC AG (CH) 2020-10-28 EP claimed
EP-3354263-A1 DRY POWDER FORMULATIONS Jagotec AG (CH) 2018-08-01 EP claimed
EP-3275435-A1 DRY POWDER FORMULATIONS Jagotec AG (CH) 2018-01-31 EP claimed
EP-1689360-B1 DRY POWDER FORMULATIONS JAGOTEC AG (CH) 2017-08-23 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20150037425-A1 POWDER COMPOSITIONS FOR INHALATION JAGOTEC AG (CH) 2015-02-05 US claimed
CN-104224720-A DRY POWDER FORMULATIONS JAGOTEC AG 2014-12-24 CN claimed
CN-101325945-B Powder compositions for inhalation JAGOTEC AG 2014-11-26 CN claimed
CN-1878537-B Dry powder formulation, method of preparing the same and dry powder inhaler using the same JAGOTEC AG 2014-08-20 CN claimed
EP-1283036-A1 Dry powder for inhalation JAGO RESEARCH AG (CH) 2003-02-12 EP claimed
WO-2002079778-A2 IN VIVO DELIVERY METHODS AND COMPOSITIONS RHEOLOGICS, INC. (US) 2002-10-10 WO claimed
WO-2002043806-A2 IN VIVO DELIVERY METHODS AND COMPOSITIONS RHEOLOGICS, INC (US) 2002-06-06 WO claimed
US-20020061835-A1 Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream RHEOLOGICS, INC. 2002-05-23 US claimed
US-20020032149-A1 Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism RHEOLOGICS, INC. 2002-03-14 US claimed
CN-1326341-A Dry powder for inhalation JIG RES AG (CH) 2001-12-12 CN claimed
US-20010044584-A1 In vivo delivery methods and compositions RHEOLOGICS, INC. 2001-11-22 US claimed
EP-1131059-A1 DRY POWDER FOR INHALATION JAGO RESEARCH AG (CH) 2001-09-12 EP claimed
EP-1004309-A1 ISRAPAFANT-CONTAINING WATER-BASE PREPARATIONS Senju Pharmaceutical Co., Ltd. (JP) 2000-05-31 EP claimed
WO-2000028979-A1 DRY POWDER FOR INHALATION JAGO RESEARCH AG (CH) 2000-05-25 WO claimed